#USA #La Jolla #CalciMedica #Auxora #Acute Pancreatitis

Introduction

CalciMedica, Inc., a clinical-stage biopharmaceutical company, has announced an important development in its quest to address acute pancreatitis (AP) – a condition that currently has no approved therapies. Following a Type C Focused Meeting with the U.S. Food and Drug Administration (FDA), CalciMedica has aligned on the design for a Phase 2b clinical trial of its investigational drug, Auxora (zegocractin). This trial represents a significant step for both the company and patients suffering from this serious inflammatory disease.

FDA Approval and Trial Design

The alignment with the FDA includes the establishment of new-onset severe respiratory failure as the primary endpoint of the trial. Additionally, key secondary endpoints will assess multi-organ failure and the time to medically indicated discharge. This regulatory agreement also identified elevated lactate dehydrogenase (LDH) levels as a potential marker to help select patients who may be at a higher risk for severe respiratory failure, further refining the trial’s focus.

Auxora aims to inhibit CRAC (calcium release-activated calcium) channels, which play a critical role in cellular functions. By doing so, it is hoped that the drug can mitigate the endothelial injury associated with AP, which often results in severe complications, notably respiratory failure. The successful targeting of these pathways could significantly influence patient outcomes, marking Auxora as a leading candidate in the treatment landscape for AP.

Historical Context and Significance

Historically, acute pancreatitis has posed significant challenges for patients and healthcare providers alike. With approximately 300,000 hospitalizations annually in the U.S. due to AP and no approved treatments available, this new trial could pave the way for innovative therapeutic solutions. According to Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica, the FDA's alignment is a crucial milestone, potentially indicating the first pivotal program in the U.S. to investigate a therapeutic candidate for acute pancreatitis. The focus on identifying patients who are particularly susceptible to severe disease underscores the importance of advancing medical protocols tailored to specific patient demographics.

Clinical Evidence and Future Prospects

CalciMedica’s decision to include LDH as an enrichment marker is bolstered by previous findings from the CARPO trial, where elevated LDH correlated with a higher number of new-onset severe respiratory failure cases among patients with AP. In the CARPO trial, Auxora demonstrated a remarkable reduction in respiratory complications among treated patients, offering promising insights into its potential efficacy.

The Phase 2b trial will also seek to confirm the patient selection criteria and assess the impact of LDH on the onset of severe respiratory failure. Discussions with the FDA will continue as CalciMedica moves forward, with the aim of finalizing the design of potential Phase 3 studies soon after the Phase 2b trial concludes.

Looking Ahead

As it stands, acute pancreatitis is characterized by a bimodal mortality pattern. Early deaths often stem from respiratory failure, while later fatalities are more related to infected pancreatic necrosis and subsequent complications. Given this complexity, the introduction of Auxora could significantly reduce both morbidity and mortality associated with AP. With continued collaboration with the FDA, CalciMedica is positioned to not only define a regulatory framework but also offer much-needed hope to patients contending with this excruciating condition.

In conclusion, CalciMedica’s advancements with Auxora signal a critical moment in the ongoing search for effective AP treatments. As they prepare for the upcoming Phase 2b trial, the biopharmaceutical community and patients alike will be keenly watching the results, potentially heralding a new era in acute pancreatitis care.